Insider transactions

EDGAR

RAPHAEL PHARMACEUTICAL INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-20.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–2 of 2

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2025-11-20 Filed 2026-04-06Louria Hayon Igal Officer: Chief Technology Officer
X

Exercise of in-the-money or at-the-money derivative security

Common Stock
Acquired (A)350,0000.01
3,500

Derived: shares × price per share. Exact value 3500.00.

1,349,000Direct (D) No— Open filing 0001213900-26-040590 Read from the filing’s XML Dispute this row
2025-11-20 Filed 2026-04-06Louria Hayon Igal Officer: Chief Technology Officer
X

Exercise of in-the-money or at-the-money derivative security

Derivative security: Warrants to purchase Common Stock — underlying Common Stock (350,000) — exercise price 0.01
Disposed (D)350,000——0Direct (D) No
F1
  • F1 The transaction reported is an exercise of warrants to purchase common stock. In accordance with General Instruction 4(c)(iii), the exercise price is reported under column 2 of this table.
Open filing 0001213900-26-040590 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

No Schedule 13D or 13G naming this issuer is in the store; this is not a statement that none were filed.

What was read

2,578,969 filings read, dated 2004-06-14 to 2026-11-19: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201517,857
2016222,642
2017222,009
2018223,345
2019216,482
2020205,260
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026262,405

Filings made before the SEC required XML are listed, not extracted.

Back to RAPHAEL PHARMACEUTICAL INC.